ClinicalTrials.gg
Status unknownNCT03618901Updated May 16, 2019

Rock Steady Boxing vs. Sensory Attention Focused Exercise

An interventional study of Rock Steady Boxing and PD SAFEx in Parkinson Disease, sponsored by Sun Life Financial Movement Disorders Research and Rehabilitation Centre. Status unknown at 1 site in Canada. Per ClinicalTrials.gov, last updated 2019-05-16.

Sponsored by Sun Life Financial Movement Disorders Research and Rehabilitation Centre · Not applicable, Interventional, and Other

The sponsor has not verified this record recently (last verified May 2019), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 10 studies in Parkinson Disease by Sun Life Financial Movement Disorders Research and Rehabilitation Centre — none open to participants now, none under way, none of them phase 3. Parkinson Disease · Sun Life Financial Movement Disorders Research and Rehabilitation Centre.

Planned enrollment
3rd of 10
60 · median 57
Started
2018
with 2 others
No phase
10 of 10
none open now
Registered
9th of 10
by date

Among the 10 studies in Parkinson Disease by Sun Life Financial Movement Disorders Research and Rehabilitation Centre, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2018, is one of 10 with no phase, and was the 9th registered.

Parkinson Disease

4,573 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 10 studies in Parkinson Disease by Sun Life Financial Movement Disorders Research and Rehabilitation Centre is open now.

Where they have run

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 63 take children under 18; 189 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Parkinson Disease by Sun Life Financial Movement Disorders Research and Rehabilitation Centre as a file.
02

Study summary

This study evaluates the effect on Rock Steady Boxing (RSB) and PD SAFEx on Parkinson's disease.

Read the detailed description

Both interventions produce benefits to the PD population. PD SAFEx has been proven to improve the motor symptoms of PD. However, research still needs to be conducted on the PD specific benefits associated with RSB. As such it an RCT is necessary to compare the effects of both interventions.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • must be able to understand verbal instructions in English
  • diagnosed with idiopathic PD by a neurologist

Exclusion criteria

Exclusion Criteria:

  • if diagnosed with a neurological condition other than PD
  • if participated in an exercise program at least 2-weeks prior to the start of the study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Rock Steady Boxing

    Non-contact boxing program.

    Other: Rock Steady Boxing

  • Active comparator
    PD SAFEx

    Sensory attention focused exercise.

    Other: PD SAFEx

Interventions

  • OtherRock Steady Boxing

    Boxing programs as offered by the Rock Steady Boxing institution,

  • OtherPD SAFEx

    Progressive proprioception training.

06

What researchers measure

Primary outcomes

  1. Motor symptom improvements

    Unified Parkinson Disease Rating Scale (UPDRS) conducted by a qualified movement disorders specialist. The maximum score is 108, the higher the score, the worse the symptoms.

    Time frame: change from baseline at 12 weeks

Secondary outcomes

  1. Quality of life assessments

    Completion of Parkinson's Disease Questionnaire (PDQ-39). There are 8 sections: mobility (sub score 10), activities of daily living (sub score 6), emotional well-being (sub score 6), stigma (sub score 4), social support (sub score 3), cognition (sub score 4), communication (sub score 3) and bodily discomfort (sub score 3). The higher the score, the worse the symptoms.

    Time frame: change from baseline at 12 weeks

  2. Balance1

    Using the Biodex balance system. The postural stability test (PST) will be conducted. The results will be presented as actual score and standard deviation for both legs to determine an individuals ability to maintain balance. The lower the score the better.

    Time frame: change from baseline at 12 weeks

  3. Gait1

    For the timed-up-and-go test (TUG) participants will stand up, walk to the line on the floor, turn around and walk back to the chair and sit down.

    Time frame: change from baseline at 12 weeks

  4. Strength

    Will be assessed using the Jamar hand dynamometer.

    Time frame: change from baseline at 12 weeks

  5. Cognitive Assessment 1

    Scale of Outcomes of Parkinson Disease (SCOPA-COG), will be used to assess memory and visuospatial function. There are 5 sections: memory learning, attention, executive functions, visuo-spatial functions and memory. The total score that can be achieved is 43 (the higher the score the better).

    Time frame: change from baseline at 12 weeks

  6. cognitive assessment 3

    Completion of Montreal Cognitive Assessment (MoCA). There are a total 30 points, the higher the score the better (26 and above is normal).

    Time frame: change from baseline at 12 weeks

  7. Balance 2

    Activities-specific Balance Confidence Scale (ABC). The total score that can be achieved is 16, the higher the percent the more self-confidence.

    Time frame: change from baseline at 12 weeks

  8. Cognitive assessment 2

    Mini-Mental State Examination (MMSE). The total score than can be achieved is otal score 30 (the higher the score the better).

    Time frame: change from baseline at 12 weeks

Other outcomes

  1. Balance3

    Balance will be measured using the mini- Balance Evaluation Systems Test (mini-best test). There are 4 sections: anticipatory, (sub score 6) reactive postural control (sub score 6), sensory orientation (sub score 6), dynamic gait (sub score 10). The total score that can be achieved is 28. The higher the score the better the balance.

    Time frame: change from baseline at 12 weeks

  2. Physical activity

    Community Healthy Activities Model Program for Seniors (CHAMPS) is a questionnaire used to assess the weekly frequency and duration of the physical activities of seniors.

    Time frame: change from baseline at 12 weeks

  3. Gait 2

    For the 6-minute walking test (6MWT) participants will be asked to walk as far as possible for 6 minutes. The further (more laps) they are able to walk the better.

    Time frame: change from baseline at 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Movement Disorders Research and Rehabilitation Centre
    Waterloo, Ontario N2L 3J4, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2018 (actual). Primary completion is estimated for Jul 2019, 10 months after the start.

Of 1,291 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 10 months is below that.

Counting every sponsor, half of 1,367 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2018
First posted
Aug 7, 2018
StartActual
Sep 30, 2018
Primary completionEst.
Jul 30, 2019
CompletionEst.
Aug 30, 2019
Last update
May 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03618901
Lead sponsor
Sun Life Financial Movement Disorders Research and Rehabilitation Centre
Responsible party
Kishoree (Graduate Student, Sun Life Financial Movement Disorders Research and Rehabilitation Centre) — Principal investigator
First posted
Aug 7, 2018
Start date
Sep 30, 2018
Primary completion
Jul 30, 2019 (estimated)
Completion
Aug 30, 2019 (estimated)
Last update
May 16, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion